GlassScriptPhysician profile
James M Kidd
NPI 1407935281
$6,891.34
in general payments reported to CMS, 2019-2025
28 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $393 · 2021: $758 · 2022: $1,268 · 2023: $1,574 · 2024: $1,324 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.46 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,093.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $854.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $843.94 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $619.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $587.61 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Csl Behring | $447.13 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $432.41 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $329.99 | 2019-2024 | Xolair |
| Pfizer INC. | $262.53 | 2019-2024 | |
| Amgen INC. | $235.78 | 2023 | Tezspire |
| Shire North American Group INC | $180.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $153.39 | 2019-2021 | |
| Grifols USA, LLC | $142.92 | 2019-2024 | Xembify |
| Kaleo, INC. | $126.97 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.67 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $81.99 | 2023 | |
| Aimmune Therapeutics, INC. | $69.42 | 2021-2022 | |
| Galderma Laboratories, L.P. | $52.63 | 2025 | Nemluvio |
| Leo Pharma INC. | $52.36 | 2022-2025 | Anzupgo |
| Octapharma USA, INC. | $39.22 | 2019 | |
| Biocryst US Sales Co., LLC | $34.37 | 2022-2024 | Orladeyo |
| Alk-Abello, INC | $32.82 | 2019-2022 | |
| Bio Products Laboratory USA, INC. | $31.54 | 2021 | |
| Tersera Therapeutics LLC | $29.28 | 2024 | Quzyttir |
| Adma Biomanufacturing LLC | $21.77 | 2020 | |
| Optinose US, INC. | $18.39 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.73 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $15.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.